tirzepatide regulatory filings The Heavy Price of GLP-1 Drugs – I-MAK FDA approves tirzepatide, Eli Lilly's

Patients should inform their anaesthetist if: They have continued taking GLP-1 medication closer to surgery than recommended They experience symptoms such as nausea, bloating, or feeling unusually full They have any concerns about their medication management By following the individualised advice from your anaesthetic and surgical team, the risk of complications can be substantially reduced whilst maintaining the important metabolic benefits these medications provide in the longer term

The incidence of anti-drug antibodies (ADA) to ZEPBOUND was evaluated in adult patients with overweight or obesity or with OSA and obesity in clinical studies lasting 52 weeks or longer

Maybe, but less than you would without Zepbound

Kirkpatrick A, Heo J, Abrol R, Goddard WA: Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor

Once released, this fat becomes available for energy production